Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use
Post Marketing Surveillance on Long Drug Use of Micombi Combination Tablets in Patients With Hypertension
Sponsor: Astellas Pharma Inc
Listed as NCT01050062, this observational or N/A phase trial focuses on Hypertension and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 7 times since 2010, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ageo, Japan , Aisho-cho, Japan , Aizubange-machi, Japan , Akashi, Japan , Akiruno, Japan , Akishima, Japan , Akune, Japan , Akō, Japan , Amagasaki, Japan , Anan, Japan and 224 more locations